A statement released earlier today by BNP PARIBAS about Fresenius (ETR:FRE) bumps the target price to 78.00EUR
- Updated: September 18, 2016
Fresenius (ETR:FRE) had its target price increased to 78EUR by BNP PARIBAS in an issued report released Monday September 19 2016. The new target price indicates a potential upside of 0.13% from the bussiness’ most recent stock close price.
Yesterday Fresenius (ETR:FRE) traded 0.00% even at 69.28EUR. Fresenius’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last close is up 0.00% from the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. 0 shares of the stock were exchanged, from ann average volume of 0.
See Graphic Below:
With a total market value of 0.0 EUR, Fresenius has a PE of 0 with a 52 week low of 0.00EUR and a 52 week high of 0.00EUR.
General Information About Fresenius (ETR:FRE)
Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.